CleanTech Company Advances Global PFAS Water Treatment Partnership with Aquatech

1. BioLargo Inc. is a billboard sponsor of Streetwise Reports and pays SWR a monthly sponsorship fee between US$3,000 and US$6,000.
2. As of the date of this article, officers, contractors, shareholders, and/or employees of Streetwise Reports LLC (including members of their household) own securities of BioLargo Inc.
3. Steve Sobek wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
4. This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company. 
5. This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

1. Disclosure for the quote from the John Newell article published on March 11, 2026

1. For the quoted article (published on March 11, 2026), the Company has paid Street Smart, an affiliate of Streetwise Reports, US$2,550.
2. Author Certification and Compensation: [John Newell of John Newell and Associates] was retained and compensated as an independent contractor by Street Smart for writing this article. Mr. Newell holds a Chartered Investment Management (CIM) designation (2015) and a  U.S. Portfolio Manager designation (2015). The recommendations and opinions expressed in this content reflect the personal, independent, and objective views of the author regarding any and all of the companies discussed. No part of the compensation received by the author was, is, or will be directly or indirectly tied to the specific recommendations or views expressed.

John Newell Disclaimer

As always it is important to note that investing in precious metals like silver carries risks, and market conditions can change violently with shock and awe tactics, that we have seen over the past 20 years. Before making any investment decisions, it's advisable consult with a financial advisor if needed. Also the practice of conducting thorough research and to consider your investment goals and risk tolerance.

2. Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

BioLargo Equipment Solutions & Technologies Inc. (BEST), a subsidiary of environmental engineering leader BioLargo Inc. (BLGO:OTCQX), announced it has entered into a memorandum of understanding (MOU) to partner with water purification leader Aquatech on making water safer worldwide, according to a May 4 release.

The company's innovative Aqueous Electrostatic Concentrator (AEC) technology is designed to extract PFAS from water, paired with downstream treatment for full PFAS management with minimal waste generation.

The companies will work together to integrate and commercialize the AEC technology and incorporate it into Aquatech’s comprehensive PFAS treatment systems, which include destruction processes, the release noted. This collaboration bolsters both companies' capabilities to offer integrated solutions that meet the stringent regulatory demands for PFAS treatment in both public and private sectors.

Aquatech, celebrated for its commitment to technical excellence and innovation in water and wastewater management, was voted Water Technology Company of the Year at the 2025 Global Water Awards, presented during the Global Water Summit in Paris. Its portfolio spans a variety of cutting-edge technologies including membrane-based, thermal, biological, electrochemical, and ultrapure water treatment solutions, BioLargo noted.

"By partnering with Aquatech — one of the most respected and capable organizations in the global water treatment industry — we can significantly amplify the reach and impact of our Aqueous Electrostatic Concentrator technology," BEST President Tonya Chandler said. "Together, we are combining proven engineering, innovative science, and deep market experience to deliver scalable PFAS treatment solutions for industrial, municipal, and government clients."

The agreement outlines a non-exclusive collaboration framework, allowing both companies to leverage their complementary technologies to better address the burgeoning needs of the PFAS remediation market, BioLargo said.

"Coupling BioLargo's AEC PFAS collection and concentration technology with Aquatech's PFAS removal and destruction expertise presents a powerful opportunity to fast-track effective solutions to serve the customer," Aquatech Environmental Services Vice President Devesh Mittal said.

BioLargo said the MOU underscores its strategic approach to forge robust alliances with industry leaders to broaden market reach and expedite the adoption of its clean technologies.

Regulations Pushing Governments to Invest in Effective PFAS Removal

The PFAS filtration market is expected to experience significant growth, expanding from US$2.34 billion in 2026 to US$3.28 billion by 2031, achieving a compound annual growth rate (CAGR) of 7% over this period. This forecast, provided by Markets and Markets, attributes the growth primarily to rising awareness of the health and environmental hazards posed by PFAS chemicals. These substances, known for their persistence in the environment, have been associated with various serious health issues including cancer, hormone disruption, and immune system effects.

In response to these concerns, governments across North America, Europe, and parts of Asia are enacting more stringent regulations concerning PFAS levels in drinking water, industrial wastewater, and consumer products. These regulatory actions are driving municipalities and industries to seek out and invest in effective PFAS removal technologies.

Rice University Tina and Sunit Patel Professor in Molecular Nanotechnology Michael S. Wong's research focuses on capturing PFAS from water and breaking them down into harmless components, potentially revolutionizing the management of these persistent pollutants.

Wong explained in a recent Expert Alert Q&A posted by the university that that PFAS are notoriously difficult to destroy due to their chemical structure. These compounds are made up of carbon-fluorine bonds, one of the strongest in chemistry, which allows them to resist natural degradation processes. This resilience makes PFAS useful in various products like cookware and textiles but also means they can persist in the environment long after their use.

Wong pointed out that water is a critical starting point for addressing PFAS.

"Water is often the most practical intervention point because it serves as a primary transport pathway for contaminants," he said. "Treating water allows for controlled, centralized mitigation before PFAS spread further through ecosystems or drinking supplies. It is also where many existing treatment infrastructures already operate, making it a logical platform for new technologies."

Distribution for Clyra's ViaCLYR™ Expanding

On May 5, BioLargo announced a win for another subsidiary, this time Clyra Medical Technologies Inc. BioLargo said Clyra has secured an exclusive distribution agreement with Al-Hikma FZCO.

Based in Dubai, United Arab Emirates, Al-Hikma FZCO will be responsible for the commercialization of ViaCLYR™ across an extensive region that includes the Gulf Cooperation Council, the Levant, North Africa, and several neighboring markets, the release said. The agreement incorporates standard international distribution terms, such as exclusivity based on performance metrics and mutual cooperation and protections typical in such agreements. Efforts to meet country-level regulatory requirements for commercial sales have already commenced in crucial areas through collaborative efforts between Clyra and Al-Hikma FZCO.

ViaCLYR™, developed by Clyra Medical, is an advanced wound irrigation solution that uses the company’s proprietary Clyrasept™ Copper-Iodine Complex Solution (CICS) technology, celebrated for its broad-spectrum antimicrobial properties, biocompatibility, and support of natural healing processes.

"Al-Hikma FZCO is exactly the kind of partner we wanted in this region — established, deeply networked across the Middle East and North Africa, and credible with regulators and the clinical community," Clyra Chief Executive Officer Steve Harrison said. "Their portfolio strength in wound management makes ViaCLYR™ a natural fit, and with regulatory work already in motion we are well positioned to build commercial momentum."

BioLargo Chief Executive Officer Dennis P. Calvert noted, "This agreement meaningfully expands Clyra's international footprint and reflects our strategy of partnering with proven, well-established distributors."

He highlighted Al-Hikma FZCO’s extensive reach, serving a population of over 500 million people in some of the world’s most dynamic healthcare markets.

"Clyra's copper-iodine technology is differentiated and aligned with our mission to bring innovative, high-quality healthcare products to the communities we serve," said Dr. Ali Farooq Abdul-Qader, founder and group CEO of Al-Hikma FZCO.

ViaCLYR™ utilizes Clyra's proprietary Copper-Iodine Complex Solution (CICS), known as Clyrasept™, which offers rapid, broad-spectrum antimicrobial activity while remaining biocompatible with human tissues. Key clinical observations included rapid reduction in wound fluid discharge, noticeable increase in healing activity early in treatment, rapid closure of wound tunnels, improved wound edge appearance, dramatic transformation of chronic, scarred wounds to actively healing wounds, and significant reduction in wound size and depth, especially in pressure injuries.

Described as a highly effective, tissue-safe, long-acting wound irrigation solution suitable for a wide range of acute and chronic wounds and burns, ViaCLYR™ is 510(k) cleared by the FDA and indicated for use in both acute and chronic wounds, boasting extremely high antimicrobial activity and sustained efficacy for up to 72 hours.

Expert Praises Co.'s Process

¹Technical Analyst John Newell of John Newell & Associates recently provided insights into BioLargo, a technology incubator actively addressing significant healthcare and environmental challenges. In his analysis for Streetwise Reports on March 11, Newell emphasized the progress BioLargo has made, particularly with its Clyra technology, which is increasingly recognized in the healthcare sector for its ability to eradicate pathogens without damaging human tissue. This capability makes Clyra an essential player in the fight against hospital-acquired infections and antibiotic resistance.

BioLargo's strategy includes advancing its proprietary technologies through rigorous scientific validation and forming partnerships with established entities to expand these innovations. The company's diverse portfolio includes solutions for advanced water treatment, environmental remediation, air quality control, long-duration energy storage, and medical technologies. Notably, Clyra Medical Technologies stands out for its copper-iodine antimicrobial solutions that remain effective for up to 72 hours and are non-cytotoxic, making them ideal for managing wounds and surgical infections. Clyra's flagship product, ViaCLYR, has secured FDA 510(k) clearance, enhancing its distribution through established medical device channels. The technology, protected by approximately 40 issued and pending patents, is available in various formats such as liquids, powders, hydrogels, and antimicrobial dressings, as noted by Newell.

In addition to its medical advancements, BioLargo is developing a long-duration energy storage system known as the Cellinity™ battery. This innovation aims to surpass the limitations of traditional lithium-ion batteries for grid-scale applications, utilizing earth-abundant materials to ensure longevity. The company plans to license this technology and collaborate with manufacturing facilities for its production.

Newell described BioLargo as a Speculative Buy, citing multiple potential catalysts across its technology platforms. The company's methodical approach to commercialization and partnership is well-suited to meet the increasing demands for advanced healthcare solutions and sustainable energy storage.

Oak Ridge Financial Analyst Richard Ryan provided an update on BioLargo on March 6. He explained, "BLGO's business model is a hub and spoke format — invent/acquire a product, prototype/prove it out, partner with necessary third parties, and commercialize." He maintains a Buy rating on the stock, noting that by commercializing technologies through operating subsidiaries, BioLargo effectively diversifies risk, retains significant ownership in its segments, and delivers solutions to diversified, high-growth end markets.

Aging Populace Creates Need for Improvements

According to a report by Future Market Insights, the global market for anti-biofilm wound dressings is projected to experience robust growth, with an expected compound annual growth rate (CAGR) of 9.8% from 2025 to 2035. The market size is anticipated to increase from US$943.5 million to US$2.4 billion during this period. This growth is largely attributed to the rising incidence of surgical site infections, diabetic ulcers, and chronic wounds. Biofilms, which are known to hinder healing and contribute to antibiotic resistance, are also a significant factor driving the demand for advanced wound care solutions.

In the United States, the market is set to expand at a CAGR of 9.3%, fueled by an aging population, the increasing prevalence of chronic wounds, advancements in medical technology, and government-led initiatives aimed at improving healthcare outcomes.

In a related market sector, Fact.MR, a global provider of market intelligence, has evaluated the global wound irrigation solution market. The market was valued at US$732 million in 2024 and is forecasted to grow at a CAGR of 3.4%, reaching US$1.02 billion by the end of 2034. This growth is driven by the increasing prevalence of chronic diseases such as diabetes and vascular conditions, which escalate the need for effective wound care. Hospitals and clinics are intensifying the adoption of wound irrigation protocols to mitigate the risk of surgical site infections, which are a major concern in healthcare settings.

On any given day, about 1 in 31 hospital patients is affected by at least one HAI, according to the Centers for Disease Control and Prevention. These infections not only lead to significant morbidity and mortality but also impose substantial financial burdens on the healthcare system. The growing awareness and consequent measures to prevent such infections are further propelling the demand for advanced wound care and irrigation solutions.

Ownership and Share Structure²

About 19.3% of BioLargo is owned by insiders and management. About 0.0367% is held by institutions with13F-disclosed institutional holdings only. The rest, 80.66%, is retail.

Its market cap is US$50.34 million, with about 320.88 million shares outstanding and about 276.31 million free-floating. It trades in a 52-week range of US$0.14 and US$0.26.